IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Victoria L ArthurEmily ShuldinerElaine F RemmersAnne HinksAlexei A GromDirk FoellAlberto MartiniMarco GattornoSeza ÖzenSampath PrahaladAndrew S ZeftJohn F BohnsackNorman T IlowiteElizabeth D MellinsRicardo RussoClaudio LenSheila OliveiraRae S M YeungAlan M RosenbergLucy R WedderburnJordi AntonJohannes-Peter HaasAngela Rösen-WolffKirsten MindenAnn Marie Szymanskinull nullWendy ThomsonDaniel L KastnerPatricia WooMichael J OmbrelloPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2018)
In our study, IL1RN was the only candidate locus associated with systemic JIA. The implicated SNPs are among the strongest known determinants of IL1RN and interleukin-1 receptor antagonist levels, linking low expression with increased systemic JIA risk. Homozygous high expression alleles predicted nonresponsiveness to anakinra therapy, making them ideal candidate biomarkers to guide systemic JIA treatment. This study is an important first step toward the personalized treatment of systemic JIA.